Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CICHOSZ, DOROTA
RESILIENT, NCT05337553 / 2022-000193-25: A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy	Active, not recruiting	3	269	Europe, US, RoW	taldefgrobep alfa, BHV-2000, BMS-986089, Placebo	Biohaven Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Inc, Biohaven Pharmaceuticals, Inc.	Spinal Muscular Atrophy, Neuromuscular Diseases, SMA	01/25	01/25